Problem of Recurrent Disease

• Most cancer patients who eventually die of their cancer can initially be rendered free of detectable disease
 
• There is a need to eliminate residual circulating cancer cells and micrometastases which may persist for long periods
 
• Additional chemotherapy or radiation therapy has only been minimally beneficial
 
• Vaccine induced or passively administered antibodies targeted against residual cells is an ideal intervention and key to long term patient survival
 
• Vaccines and antibodies developed by Drs. Livingston and Ragupathi have substantial proof of concept and clinical evidence supporting this approach
 
• Treatments for the key metastatic cancers MabVax is focusing on could generate annual revenues of $500M